Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an announcement.
Sihuan Pharmaceutical Holdings Group Ltd. announced the publication of the prospectus for the proposed spin-off and separate listing of Xuanzhu Biopharm on the Main Board of the Hong Kong Stock Exchange. The global offering will include 67,333,500 H Shares, representing 13% of Xuanzhu Biopharm’s total issued share capital, with an expected offer price of HK$11.60 per share. The spin-off and listing are contingent upon approval from the Stock Exchange and market conditions, with no guarantee of proceeding, urging shareholders to exercise caution.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, primarily operating in the pharmaceutical industry. The company focuses on the development and commercialization of pharmaceutical products, with a particular emphasis on innovative drugs and biopharmaceuticals.
YTD Price Performance: 173.28%
Average Trading Volume: 88,366,287
Technical Sentiment Signal: Buy
Current Market Cap: HK$16.7B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.